News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
|Title||[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Pan C-Y, Ji L-N, Lu J-M, Yang W-Y, Zhou Z-G, Zou D-J, Ji Q-H, Han P, Liu J, Li Q, Su B-L, Li Y-B, Gao Z-N, Wang P-H, Yin S-N, Dong Y-H, Yang T, Sun K, Li H, Hong X, Lin J, Shi J-M, Yang X-J, Fang H, Yan X-D|
|Corporate Authors||SOLVE™ Chinese study group|
|Journal||Zhonghua nei ke za zhi [Chinese journal of internal medicine]|
|Date Published||2013 Jan|
Study of Once-daily LeVEmir(®) (SOLVE(TM)) was a 24-week international observational study to evaluate the safety and effectiveness of initiating once-daily insulin detemir (Levemir) as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who failed treatment of oral anti-diabetic drugs (OAD).
|Alternate Journal||Zhonghua Nei Ke Za Zhi|